| Quarterly Consolidated Statement of Operations and Other Comprehensive Loss |
The following table sets forth our quarterly Consolidated Statement of Operations and Other Comprehensive Loss (unaudited) data through the years ended December 31, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2021 |
|
Q2 2021 |
|
Q3 2021 |
|
Q4 2021 |
|
Q1 2022 |
|
Q2 2022 |
|
Q3 2022 |
|
Q4 2022 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
|
$’000 |
| Revenue |
71,293 |
|
|
57,478 |
|
|
74,462 |
|
|
117,594 |
|
|
266,446 |
|
|
265,362 |
|
|
288,898 |
|
|
288,963 |
|
| Claims expense |
(23,917) |
|
|
(40,384) |
|
|
(51,298) |
|
|
(104,026) |
|
|
(247,552) |
|
|
(238,764) |
|
|
(264,283) |
|
|
(266,404) |
|
| Clinical care delivery expense |
(11,823) |
|
|
(16,013) |
|
|
(17,038) |
|
|
(24,957) |
|
|
(23,927) |
|
|
(21,649) |
|
|
(18,505) |
|
|
(16,543) |
|
| Platform & application expenses |
(4,718) |
|
|
(12,472) |
|
|
(4,852) |
|
|
(10,681) |
|
|
(13,748) |
|
|
(6,567) |
|
|
(5,074) |
|
|
(4,508) |
|
| Research & development expenses |
(16,246) |
|
|
(12,667) |
|
|
(25,195) |
|
|
(14,365) |
|
|
(17,314) |
|
|
(27,577) |
|
|
(23,008) |
|
|
(11,256) |
|
| Sales, general & administrative expenses |
(30,986) |
|
|
(43,753) |
|
|
(39,257) |
|
|
(73,176) |
|
|
(55,649) |
|
|
(64,503) |
|
|
(54,474) |
|
|
(53,311) |
|
| Impairment expense |
—
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(24,820) |
|
|
(647) |
|
|
(38,599) |
|
| Depreciation and amortization expenses |
(713) |
|
|
(1,310) |
|
|
(2,659) |
|
|
(4,503) |
|
|
(3,078) |
|
|
(3,906) |
|
|
(2,456) |
|
|
(2,610) |
|
| Premium deficiency reserve (expense) / income |
(1,179) |
|
|
(25) |
|
|
2,870 |
|
|
(48,199) |
|
|
(6,868) |
|
|
9,123 |
|
|
21,518 |
|
|
7,538 |
|
| Loss from operations |
(18,289) |
|
|
(69,146) |
|
|
(62,967) |
|
|
(162,313) |
|
|
(101,690) |
|
|
(113,301) |
|
|
(58,031) |
|
|
(96,730) |
|
| Interest expense |
(1,083) |
|
|
(1,309) |
|
|
(1,684) |
|
|
(8,971) |
|
|
(5,982) |
|
|
(9,192) |
|
|
(8,255) |
|
|
(9,307) |
|
| Interest income |
14 |
|
|
14 |
|
|
2 |
|
|
295 |
|
|
255 |
|
|
128 |
|
|
284 |
|
|
374 |
|
| Loss on settlement of warrants |
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,375) |
|
|
(22) |
|
|
— |
|
| Gain / (loss) on fair value remeasurement |
— |
|
|
— |
|
|
— |
|
|
239,195 |
|
|
78,773 |
|
|
99,957 |
|
|
11,249 |
|
|
2,770 |
|
| Exchange (loss) / gain |
(573) |
|
|
482 |
|
|
(396) |
|
|
1,270 |
|
|
(447) |
|
|
(7,350) |
|
|
(4,848) |
|
|
2,225 |
|
| Gain on sale of subsidiary |
3,917 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
| Share of net loss on equity method investments |
(455) |
|
|
(821) |
|
|
(1,017) |
|
|
(1,046) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
| Net loss before taxation |
(16,469) |
|
|
(70,780) |
|
|
(66,062) |
|
|
68,430 |
|
|
(29,091) |
|
|
(32,133) |
|
|
(59,623) |
|
|
(100,668) |
|
| Tax (provision) / benefit |
(8) |
|
|
2,501 |
|
|
(7) |
|
|
(1,043) |
|
|
(9) |
|
|
(199) |
|
|
(280) |
|
|
554 |
|
| Net loss |
(16,477) |
|
|
(68,279) |
|
|
(66,069) |
|
|
67,387
|
|
|
(29,100) |
|
|
(32,332) |
|
|
(59,903) |
|
|
(100,114) |
|
|